查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529818

尿失禁治療藥物市場規模、佔有率、趨勢分析報告：按類型、藥物類別、性別、分銷管道、地區、細分市場預測，2024-2030年

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress, Urge, Overflow, Functional Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模及趨勢

由於人口老化中尿失禁（UI）盛行率的增加以及對可用治療方案的認知不斷增強，預計到2023 年，尿失禁藥物的全球市場規模將達到43.7 億美元，預計將以複合年成長率擴大。根據Dovepress 2023年5月的報告，女性尿失禁的盛行率為24.8%，其中壓力性尿失禁最常見，為12.7%，其次是混合性尿失禁，為8.0%，急性尿失禁為4.1%。這項研究強調，UI 的盛行率隨著年齡和體重指數 (BMI) 的增加而逐漸增加。

該市場包括多種藥物，包括抗膽鹼能藥物、BETA3-腎上腺素促效劑和局部雌激素。這些藥物透過減少膀胱收縮、增加膀胱容量以及強化尿道和陰道組織來幫助控制症狀。市場參與者不斷投資於研發，以推出更有效、更安全的治療方法，這推動了市場的成長。

人口老化是該市場成長的主要動力。隨著全球預期壽命的延長，老年人口數量不斷增加，導致包括 UI 在內的與老齡化相關的疾病的盛行率增加。由於骨盆底肌肉衰弱、膀胱容量減少以及其他影響泌尿功能的健康狀況，老年人經常會出現膀胱控制問題。這種人口結構的變化極大地促進了對治療藥物解決方案不斷成長的需求，以管理和緩解這些疾病。

在全球範圍內，60 歲及以上的人口預計將從 2020 年的 10 億增加一倍，達到 2050 年的 21 億。隨著人口老化，UI 和其他老年綜合症（如跌倒和譫妄）的負擔預計會增加。這種成長需要更有效和更容易獲得的治療方法，從而推動了這一領域的研究和發展。因此，醫療保健提供者致力於透過更好地管理 UI 來提高老年人的生活品質。因此，市場正在擴大，公司正在投資創新療法，以滿足不斷成長的患者群體的需求。

此外，藥物開發的進步也為該市場的成長做出了重大貢獻。研究人員和製藥公司致力於開發療效更好、副作用更少、給藥方法更改良的新藥。緩釋性和聯合治療等創新正在改善患者的依從性和藥物結果。例如，2024 年 4 月，Lupin Ltd 在美國推出了Mirabegron），這是 Mybetriq 的非專利替代品，用於治療膀胱過動症。此外，對新藥物標靶和作用機制的探索正在導致更有效的治療藥物的引入。這些進步不僅改善了患者的生活品質，還透過提供優質的治療選擇推動了市場擴張。

此外，近年來，人們對尿失禁的認知和診斷顯著增加。醫療機構和製藥公司所進行的健康宣傳活動和教育計畫在減少與這種疾病相關的恥辱和鼓勵人們尋求醫療建議方面發揮著重要作用。此外，診斷工具和方法的改進使醫療保健專業人員更容易識別和分類不同類型的尿失禁，從而製定更個人化和有效的治療計劃。由於認知的提高和診斷能力的提高，尿失禁治療藥物的患者基礎正在擴大。

全球尿失禁藥物市場細分報告

該報告預測了2018年至2030年國家層級的收益成長，並對每個子區隔的最新行業趨勢和商機進行了分析。研究報告按類型、性別、分銷管道、藥物類別和地區對全球尿失禁治療藥物市場進行分類。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章：尿失禁藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 尿失禁治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章 尿失禁治療藥物市場：按類型估計和趨勢分析

  • 尿失禁治療藥物細分市場細分儀表板
  • 尿失禁治療藥物市場：按類型的變化分析
  • 不同類型尿失禁治療藥物市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 應力性尿失禁
  • 急性尿失禁
  • 溢流性尿失禁
  • 功能性失禁
  • 其他

第5章 尿失禁治療藥物市場：依藥物類別估計與趨勢分析

  • 尿失禁治療藥物細分市場細分儀表板
  • 尿失禁治療藥物市場：依藥物類別波動分析
  • 按藥物類別分類的尿失禁治療藥物市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 抗膽鹼能藥物
  • Beta3腎上腺素受體促效劑
  • α阻斷劑
  • 雌激素
  • 去氨加壓素
  • 三環抗憂鬱藥物
  • 其他

第6章 尿失禁治療藥物市場：依通路估算與趨勢分析

  • 尿失禁治療藥物細分市場細分儀表板
  • 尿失禁治療藥物市場：按分銷管道波動分析
  • 按分銷管道分類的尿失禁治療藥物市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 尿失禁治療藥物市場：性別、估計與趨勢分析

  • 尿失禁治療藥物細分市場細分儀表板
  • 尿失禁治療藥物市場：性別差異分析
  • 性別尿失禁治療藥物市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 男性
  • 女士

第8章 尿失禁治療藥物市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • Pfizer Inc.
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals
Product Code: GVR-4-68040-366-2

Market Size & Trends

The global urinary incontinence therapeutics market size was estimated at USD 4.37 billion in 2023 and is projected to expand at a CAGR of 4.0% from 2024 to 2030 due to the increasing prevalence of urinary incontinence (UI) among aging populations and the rising awareness about available treatments. According to a May 2023 report by Dovepress, the prevalence of female UI was found to be 24.8%, with stress UI being the most common subtype at 12.7%, followed by mixed UI at 8.0%, and urgency UI at 4.1%. The study highlighted that the prevalence of UI increased progressively with age and body mass index (BMI).

This market includes a variety of medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogens. These drugs help manage symptoms by reducing bladder contractions, increasing bladder capacity, and strengthening urethral and vaginal tissues. Market players are continuously investing in research and development to introduce more effective and safer treatments, which is propelling market growth.

The aging population is majorly driving the growth of this market. As global life expectancy increases, the number of elderly individuals is rising, leading to a higher prevalence of age-related conditions, including UI. Older adults often experience bladder control issues due to weakened pelvic floor muscles, decreased bladder capacity, and other health conditions that impact urinary function. This demographic shift significantly contributes to the growing demand for therapeutic solutions to manage and alleviate these symptoms.

Globally, the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As the population ages, the burden of UI and other geriatric syndromes like falls and delirium is expected to grow. This increase necessitates more effective and accessible treatments, driving research and development in this sector. Consequently, healthcare providers are focusing on improving the quality of life for older adults through better management of UI. As a result, the market is expanding, with companies investing in innovative treatments to meet the needs of this growing patient population.

In addition, advancements in drug development are significantly contributing to the growth of this market. Researchers and pharmaceutical companies are focusing on developing new drugs with better efficacy, fewer side effects, and improved delivery methods. Innovations such as extended-release formulations and combination therapies are enhancing patient compliance and treatment outcomes. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Mybetriq, aimed at managing overactive bladder in the U.S. Additionally, the exploration of novel drug targets and mechanisms of action is leading to the introduction of more effective therapies. These advancements not only improve the quality of life for patients but also drive market expansion by offering superior treatment options.

Furthermore, there has been a notable increase in awareness and diagnosis of urinary incontinence in recent years. Health campaigns and educational programs by healthcare organizations and pharmaceutical companies have played a crucial role in reducing the stigma associated with this condition and encouraging individuals to seek medical advice. Improved diagnostic tools and methods have also made it easier for healthcare providers to identify and classify different types of urinary incontinence, leading to more personalized and effective treatment plans. This heightened awareness and better diagnostic capabilities are expanding the patient base for UI therapeutics.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, gender, distribution channel, drug class, and region.

  • Type Outlook (Revenue, USD Billion; 2018 - 2030)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Other Types
  • Drug Class Outlook (Revenue, USD Billion; 2018 - 2030)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other Drug Classes
  • Gender Outlook (Revenue, USD Billion; 2018 - 2030)
  • Male
  • Female
  • Distribution Channel Outlook (Revenue, USD Billion; 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Billion; 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Age
    • 1.2.3. Distribution Channel
    • 1.2.4. Drug Class
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Age outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Drug class outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Urinary Incontinence Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 4.2. Urinary Incontinence Therapeutics Market: Type Movement Analysis
  • 4.3. Urinary Incontinence Therapeutics Market by Type Outlook (USD Billion)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Stress Incontinence
    • 4.5.1. Stress Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Urge Incontinence
    • 4.6.1. Urge Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Overflow Incontinence
    • 4.7.1. Overflow Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.8. Functional Incontinence
    • 4.8.1. Functional Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 5.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 5.2. Urinary Incontinence Therapeutics Market: Drug Class Movement Analysis
  • 5.3. Urinary Incontinence Therapeutics Market by Drug Class Outlook (USD Billion)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Anticholinergics
    • 5.5.1. Anticholinergics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Beta-3 Adrenoceptor Agonists
    • 5.6.1. Beta-3 Adrenoceptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Alpha Blockers
    • 5.7.1. Alpha Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. Estrogen
    • 5.8.1. Estrogen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Desmopressin
    • 5.9.1. Desmopressin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Tricyclic Antidepressants
    • 5.10.1. Tricyclic Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.11. Others
    • 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Urinary Incontinence Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 6.2. Urinary Incontinence Therapeutics Market: Distribution Channel Movement Analysis
  • 6.3. Urinary Incontinence Therapeutics Market by Distribution Channel Outlook (USD Billion)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Retail Pharmacies
    • 6.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Online Pharmacies
    • 6.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Urinary Incontinence Therapeutics Market: Gender Estimates & Trend Analysis

  • 7.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 7.2. Urinary Incontinence Therapeutics Market: Gender Movement Analysis
  • 7.3. Urinary Incontinence Therapeutics Market by Gender Outlook (USD Billion)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Male
    • 7.5.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Female
    • 7.6.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Pfizer Inc.
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Age benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. AbbVie Inc.
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Age benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Astellas Pharma Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Age benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Johnson & Johnson
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Age benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Viatris Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Age benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Teva Pharmaceutical Industries Ltd.
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Age benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Sanofi S.A.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Age benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. GlaxoSmithKline plc
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Age benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Age benchmarking
      • 9.2.9.4. Strategic initiatives
      • 9.2.9.5. Strategic initiatives
      • 9.2.9.6. Strategic initiatives
    • 9.2.10. Bayer AG
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Age benchmarking
      • 9.2.10.4. Strategic initiatives
      • 9.2.10.5. Strategic initiatives
    • 9.2.11. Ferring Pharmaceuticals
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Age benchmarking
      • 9.2.11.4. Strategic initiatives
      • 9.2.11.5. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 4. Global urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 5. Global urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 6. Global urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 7. North America urinary incontinence therapeutics market, by region, 2018 - 2030, (USD Billion)
  • Table 8. North America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 9. North America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 10. North America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 11. North America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 12. U.S. urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 13. U.S. urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 14. U.S. urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 15. U.S. urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 16. Canada urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 17. Canada urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 18. Canada urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 19. Canada urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 20. Mexico urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 21. Mexico urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 22. Mexico urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 23. Mexico urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 24. Europe urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 25. Europe urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 26. Europe urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 27. Europe urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 28. Europe urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 29. UK urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 30. UK urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 31. UK urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 32. UK urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 33. Germany urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 34. Germany urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 35. Germany urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 36. Germany urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 37. France urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 38. France urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 39. France urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 40. France urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 41. Italy urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 42. Italy urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 43. Italy urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 44. Italy urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 45. Spain urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 46. Spain urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 47. Spain urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 48. Spain urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 49. Denmark urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 50. Denmark urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 51. Denmark urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 52. Denmark urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 53. Norway urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 54. Norway urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 55. Norway urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 56. Norway urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 57. Sweden urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 58. Sweden urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 59. Sweden urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 60. Sweden urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 61. Asia Pacific urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 62. Asia Pacific urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 63. Asia Pacific urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 64. Asia Pacific urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 65. Asia Pacific urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 66. Japan urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 67. Japan urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 68. Japan urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 69. Japan urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 70. China urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 71. China urinary incontinence therapeutics market, by gender 2018 - 2030, (USD Billion)
  • Table 72. China urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 73. China urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 74. India urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 75. India urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 76. India urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 77. India urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 78. Australia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 79. Australia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 80. Australia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 81. Australia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 82. South Korea urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 83. South Korea urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 84. South Korea urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 85. South Korea urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 86. Thailand urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 87. Thailand urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 88. Thailand urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 89. Thailand urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 90. Latin America urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 91. Latin America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 92. Latin America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 93. Latin America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 94. Latin America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 95. Brazil urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 96. Brazil urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 97. Brazil urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 98. Brazil urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 99. Argentina urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 100. Argentina urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 101. Argentina urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 102. Argentina urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 103. Middle East & Africa urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 104. Middle East & Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 105. Middle East & Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 106. Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 107. Middle East & Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 108. South Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 109. South Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 110. South Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 111. South Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 112. Saudi Arabia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 113. Saudi Arabia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 114. Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 115. Saudi Arabia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 116. UAE urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 117. UAE urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 118. UAE urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 119. UAE urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 120. Kuwait urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 121. Kuwait urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 122. Kuwait urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 123. Kuwait urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)

List of Figures

  • Fig. 1. Information procurement
  • Fig. 2. Primary research pattern
  • Fig. 3. Market research approaches
  • Fig. 4. Value chain-based sizing & forecasting
  • Fig. 5. Market formulation & validation
  • Fig. 6. Urinary incontinence therapeutics market segmentation
  • Fig. 7. Market driver analysis (current & future impact)
  • Fig. 8. Market restraint analysis (current & future impact)
  • Fig. 9. SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10. Porter's five forces analysis
  • Fig. 11. Urinary incontinence therapeutics market, type outlook key takeaways (USD billion)
  • Fig. 12. Urinary incontinence therapeutics market: type movement analysis (USD billion), 2023 & 2030
  • Fig. 13. Stress incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 14. Urge incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 15. Overflow Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 16. Functional Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 17. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 18. Urinary incontinence therapeutics market, gender outlook key takeaways (USD billion)
  • Fig. 19. Urinary incontinence therapeutics market: gender movement analysis (USD billion), 2023 & 2030
  • Fig. 20. Male market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 21. Female market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 22. Urinary incontinence therapeutics market, distribution channel outlook key takeaways (USD billion)
  • Fig. 23. Urinary incontinence therapeutics market: distribution channel movement analysis (USD billion), 2023 & 2030
  • Fig. 24. Hospital pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 25. Retail pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 26. Online pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 27. Urinary incontinence therapeutics market, drug class outlook key takeaways (USD billion)
  • Fig. 28. Urinary incontinence therapeutics market: drug class movement analysis (USD billion), 2023 & 2030
  • Fig. 29. Anticholinergics market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 30. Beta-3 adrenoceptor agonists market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 31. Alpha blockers market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 32. Estrogen market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 33. Desmopressin market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 34. Tricyclic antidepressants market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 35. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 36. Urinary incontinence therapeutics market: regional key takeaways (USD billion)
  • Fig. 37. Urinary incontinence therapeutics market: regional outlook, 2023 & 2030, USD billion
  • Fig. 38. North America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 39. U.S. urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 40. Canada urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 41. Mexico urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 42. Europe urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 43. UK urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 44. Germany urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 45. France urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 46. Spain urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 47. Italy urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 48. Norway urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 49. Denmark urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 50. Sweden urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 51. Asia Pacific urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 52. China urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 53. Japan urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 54. India urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 55. South Korea urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 56. Australia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 57. Thailand urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 58. Latin America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 59. Brazil urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 60. Argentina urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 61. Middle East and Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 62. South Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 63. Saudi Arabia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 64. UAE urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 65. Kuwait urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 66. List of key emerging company's/distribution channel disruptors/innovators